Canada markets close in 47 minutes

Cue Biopharma, Inc. (CUE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3200-0.0500 (-1.48%)
As of 03:13PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close3.3700
Open3.3700
Bid3.2800 x 900
Ask3.3100 x 1100
Day's Range3.2757 - 3.4200
52 Week Range2.3600 - 18.4200
Volume87,652
Avg. Volume368,911
Market Cap117.467M
Beta (5Y Monthly)1.72
PE Ratio (TTM)N/A
EPS (TTM)-1.4420
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.80
  • GlobeNewswire

    Cue Biopharma Reports Second Quarter 2022 Financial Results

    BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today second quarter 2022 financial results. The Company will host a business update call and webcast on Tuesday, August 23, 2022 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s websit

  • Simply Wall St.

    Here's What Cue Biopharma, Inc.'s (NASDAQ:CUE) Shareholder Ownership Structure Looks Like

    A look at the shareholders of Cue Biopharma, Inc. ( NASDAQ:CUE ) can tell us which group is most powerful. Large...

  • GlobeNewswire

    Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

    BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the Guggenheim I&I Spotlight Series – Treg-based Therapies being held July 12–13, 2022. Presentation DetailsGuggenheim I&I Spotlight Series – Treg-based TherapiesDate and Time: